Drugs & Therapy Perspectives

, Volume 25, Issue 12, pp 14–18 | Cite as

The choice of initial monotherapy in newly diagnosed epilepsy requires careful consideration of multiple factors

Disease Management


  1. 1.
    Stein MA, Kanner AM. Management of newly diagnosed epilepsy: a practical guide to monotherapy. Drugs 2009; 69(2): 199–222PubMedCrossRefGoogle Scholar
  2. 2.
    Shorvon S. Handbook of epilepsy treatment. 2nd ed. Malden (MA): Blackwell, 2005CrossRefGoogle Scholar
  3. 3.
    National Institute for Clinical Excellence. Newer drugs for epilepsy in adults. Technology Appraisal 76, March 2004. London: NICE, 2004Google Scholar
  4. 4.
    Hauser WA, Rich SS, Lee JRJ, et al. Risk of recurrent seizures after two unprovoked seizures. N Engl J Med 1998 Feb 12; 338(7): 429–34PubMedCrossRefGoogle Scholar
  5. 5.
    Wolf P. International classification of the epilepsies. In: Engel Jr J, Pedley TA, editors. Epilepsy: a comprehensive textbook. Philadelphia (PA): Lippincott-Raven, 1998: 773–7Google Scholar
  6. 6.
    Levy RH, Mattson RH, Meldrum BS, et al, editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2002Google Scholar
  7. 7.
    Cross SA, Durran MP. Lacosamide in partial onset seizures. Drugs 2009; 69(4): 449–59PubMedCrossRefGoogle Scholar
  8. 8.
    Deeks ED, Scott LJ. Rufinamide. CNS Drugs 2006; 20(9): 751–60PubMedCrossRefGoogle Scholar
  9. 9.
    Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007 Mar 24; 369(9566): 1000–15PubMedCrossRefGoogle Scholar
  10. 10.
    Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007 Mar 24; 369(9566): 1016–26PubMedCrossRefGoogle Scholar
  11. 11.
    Chung AM, Eiland LS. Use of second-generation antiepileptic drugs in the pediatric population. Pediatr Drugs 2008; 10(4): 217–54CrossRefGoogle Scholar
  12. 12.
    Privitera MD. Generic antiepileptic drugs: current controversies and future directions. Epilepsy Curr 2008 Sep–Oct; 8(5): 113–7PubMedCrossRefGoogle Scholar
  13. 13.
    Van Paesschen W, Hauman H, Lagae L. The use of generic medication in epilepsy: a review of potential issues and challenges. Eur J Paediatr Neurol 2009 Mar; 13(2): 87–92PubMedCrossRefGoogle Scholar
  14. 14.
    Arroyo S, Kramer G. Treating epilepsy in the elderly: safety considerations. Drug Saf 2001; 24(13): 991–1015PubMedCrossRefGoogle Scholar
  15. 15.
    Battino D, Tomson T. Management of epilepsy during pregnancy. Drugs 2007; 67(18): 2727–46PubMedCrossRefGoogle Scholar
  16. 16.
    Crawford PM. Managing epilepsy in women of childbearing age. Drug Saf 2009; 32(4): 293–307PubMedCrossRefGoogle Scholar
  17. 17.
    Meador KJ, Baker GA, Finnell RH, et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology 2006 Aug; 67(3): 407–12PubMedCrossRefGoogle Scholar
  18. 18.
    Holmes LB, Baldwin EJ, Smith CR, et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 2008 May; 70 (22 Pt 2): 2152–8PubMedCrossRefGoogle Scholar
  19. 19.
    Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000 Feb 3; 342(5): 314–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Personalised recommendations